01—Abstract
Summary
Summary of the 8-K filed February 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Pfizer reported fourth-quarter and full-year 2024 results on February 4, 2025, with full-year revenues of $63.6 billiona, up 7% operationally, and fourth-quarter revenues of $17.8 billion, up 21% operationally.
The headline growth is flattered by a one-time $3.5 billionb Paxlovid revenue reversal in fourth-quarter 2023, so the cleaner signal is the 12% operational growth in non-COVID products for the full year. Full-year reported diluted EPS was $1.41 and adjusted diluted EPS was $3.11, while fourth-quarter reported EPS was $0.07 and adjusted EPS was $0.63, the latter depressed by $2.9 billion of non-cash intangible asset impairments. Management reaffirmed all components of 2025 guidance: revenues of $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00.
The company raised its cost realignment savings target to approximately $4.5 billionc by the end of 2025 and expects to earn $1.5 billion of net savings from the first phase of its Manufacturing Optimization Program by 2027. Guidance assumes about $0.6 billion of revenue erosion from generic and biosimilar competition and no share repurchases in 2025, as Pfizer prioritizes deleveraging following the $43.4 billion Seagen acquisition. Capital allocation remains constrained: no buybacks were executed in 2024, dividends totaled $9.5 billion, and internal R&D spending was $10.8 billion.
Pfizer expects to de-lever sufficiently by year-end 2025 to shift toward a more balanced capital allocation strategy, which could include business development or renewed buybacks. Recent pipeline news was mixed, with positive Phase 3 results for Braftovi (BREAKWATER) and sasanlimab (CREST), offset by a Phase 3 DMD program discontinuation and impairment charges. Pfizer also sold about 700 million Haleon shares for roughly $3.0 billiond in January 2025, reducing its stake from roughly 15% to 7%.
02—Key points
Key Highlights
- Full-year 2024 revenues of $63.6 billion grew 7% operationally; excluding Comirnaty and Paxlovid, revenues grew 12%.
- Fourth-quarter 2024 revenues of $17.8 billion rose 22% reported, but the comparison is inflated by a $3.5 billion one-time Paxlovid reversal in Q4 2023.
- Full-year adjusted diluted EPS was $3.11 (up 69%) versus reported diluted EPS of $1.41; Q4 adjusted EPS of $0.63 absorbed $2.9 billion in non-cash impairments.
- 2025 guidance reaffirmed: revenues of $61.0–$64.0 billion and adjusted diluted EPS of $2.80–$3.00, assuming no share repurchases.
- Cost realignment savings target raised to approximately $4.5 billion by end-2025; $1.5 billion in Manufacturing Optimization savings expected by 2027.
- Capital returns are constrained: no buybacks in 2024, $9.5 billion in dividends paid, and $3.3 billion of buyback authorization remaining.
- Sold about 700 million Haleon shares for roughly $3.0 billion in January 2025, cutting its stake from about 15% to 7%.
03—Questions
Frequently Asked Questions
Is Pfizer's 2024 revenue growth sustainable without COVID products?
Excluding Comirnaty and Paxlovid, revenues grew 12% operationally in 2024, driven by Vyndaqel (up 64% for the year), Eliquis, Xtandi, Nurtec, and the newly acquired legacy Seagen portfolio ($3.4 billion). Offsetting this, Comirnaty and Xeljanz declined sharply, and 2025 guidance includes about $0.6 billion of generic and biosimilar erosion.
Why do reported and adjusted EPS differ so much?
Reported full-year EPS of $1.41 includes amortization of intangibles ($5.3 billion), acquisition-related items, and certain significant items such as asset impairments ($3.3 billion) and restructuring costs. Adjusted EPS of $3.11 excludes these, which is the measure management uses for guidance, though investors should weigh the recurring nature of some excluded charges.
When might Pfizer resume share buybacks or increase business development?
Management expects to sufficiently de-lever its balance sheet by the end of 2025, after which it plans a more balanced capital allocation strategy. This could include value-creating business development deals or renewed share repurchases, but current guidance assumes no buybacks in 2025.
What were the notable pipeline developments disclosed?
Positive Phase 3 results were reported for Braftovi (BREAKWATER, showing PFS and OS improvement in colorectal cancer) and sasanlimab (CREST, in bladder cancer). Pfizer discontinued its DMD program, which led to a $240 million impairment and a $420 million facility-related charge, and took $2.9 billion in impairments in Q4 2024 on assets including B7H4V and Medrol.
What does the Haleon stake sale mean for Pfizer?
The January 2025 sale of 700 million Haleon shares for about $3.0 billion reduced Pfizer's ownership from roughly 15% to 7%. This provides cash for de-leveraging and reduces future equity-method and fair-value income volatility tied to Haleon, though it removes a source of non-operating gains that boosted 2024 results.
04—Continue